Lineage Cell Therapeutics (LCTX) Long-Term Deferred Tax (2013 - 2026)

Lineage Cell Therapeutics' Long-Term Deferred Tax history runs 10 years deep, the most recent figure standing at $5.8 million for Q1 2026.

• In Q1 2026, Long-Term Deferred Tax changed N/A year-over-year to $5.8 million; the TTM figure through Mar 2026 stood at $5.8 million (changed N/A YoY), while the FY2025 annual figure was $5.8 million, up 2024.54% from the prior year.
• Long-Term Deferred Tax for Q1 2026 stood at $5.8 million, roughly flat from $5.8 million in the prior quarter.
• The five-year high for Long-Term Deferred Tax was $5.8 million in Q4 2025, with the low at $273000.0 in Q4 2024.
• The 3-year median for Long-Term Deferred Tax is $5.8 million (2025), against an average of $4.0 million.
• Peak annual rise in Long-Term Deferred Tax reached 2024.54% in 2025, while the deepest fall reached 2024.54% in 2025.
• Lineage Cell Therapeutics' Long-Term Deferred Tax stood at $273000.0 in 2024, then jumped by 2024.54% to $5.8 million in 2025, then changed by 0.0% to $5.8 million in 2026.
• Business Quant data shows LCTX's Long-Term Deferred Tax at $5.8 million in Q1 2026, $5.8 million in Q4 2025, and $273000.0 in Q4 2024.